Approximately 7% of Gilead Sciences’ personnel will be laid off as a result of a business evaluation being conducted on the company’s Kite Pharma cell therapy division.
In a communication to the staff this week, Cindy Perettie, Kite Pharma’s leading executive, provided a glimpse of a “refreshed business strategy.” This strategy aims to realign the company’s strategic goals for enhanced patient care.
“As a result of this careful review, certain functions are reorganizing their team structures to optimize how we deliver on our strategy,” the letter detailed.
“In some cases, we are also making the decision to reduce the number of roles in certain areas of our business that are not aligned to our refreshed strategic priorities and in areas where there may be more efficient ways to achieve those priorities, which may impact some team members.”
90 new positions are being established that are more in line with Gilead’s goals, and the overall impact of personnel changes is around 5%, as per the spokesman’s statement.
Perettie added, “We have made difficult decisions, but we believe these changes will help position the company for more sustainable growth and enable us to reach more patients.”
© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.